Literature DB >> 6876570

Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease.

M B De Paepe, K H Schelstraete, S M Ringoir, N H Lameire.   

Abstract

To evaluate the effect of continuous ambulatory peritoneal dialysis (CAPD) on the anemia of endstage renal disease, serial measurements of red cell mass and other hematological parameters were performed in 34 patients. Twenty-five patients were measured at the start and at 6 months (group 1), 13 at the start, at 6 and 12 months (group 2), and 11 were followed during their second year of treatment with measurements at 12, 18, and 24 months (group 3). In group 1 the hematocrit rose from 24.6 +/- 0.9 to 29.9 +/- 0.8% (P less than 0.01). The red cell mass increased from 879 +/- 44 to 1019 +/- 47 ml (P less than 0.01). The calculated plasma volume decreased from 2915 +/- 174 to 2568 +/- 136 ml (P less than 0.01). In group 2 at 6 months the hematocrit rose from 24.7 +/- 1.2 to 30.7 +/- 1.0% (P less than 0.01); the red cell mass increased from 924 +/- 66 to 1059 +/- 71 ml (P less than 0.05). The calculated plasma volume decreased at 6 months from 3001 +/- 201 to 2555 +/- 170 ml (P less than 0.01). No significant changes occurred between 6 and 12 months. In group 3 no significant changes in hematocrit, red cell mass, or plasma volume were observed. It is concluded that the rise in hematocrit in CAPD patients is due to an increase in red cell mass and also to a decrease in plasma volume. These changes are manifest within 6 months of treatment. The rise in red cell mass represents an improvement in renal anemia in these patients.

Entities:  

Mesh:

Year:  1983        PMID: 6876570     DOI: 10.1038/ki.1983.88

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Continuous ambulatory peritoneal dialysis after the honeymoon: review of experience in Newcastle 1979-84.

Authors:  A Heaton; R S Rodger; L Sellars; T H Goodship; K Fletcher; N Nikolakakis; M K Ward; R Wilkinson; D N Kerr
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

2.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

Review 3.  The use of erythropoietin in renal failure.

Authors:  I C Macdougall; R D Hutton; G A Coles; J D Williams
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

Review 4.  Is peritoneal dialysis a good long term treatment?

Authors:  G A Coles
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

5.  One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis.

Authors:  G Offner; P F Hoyer; K Latta; L Winkler; J Brodehl; P Scigalla
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 6.  Erythropoiesis and erythropoietin levels in renal transplant recipients.

Authors:  M Wolff; W Jelkmann
Journal:  Klin Wochenschr       Date:  1991-01-22

Review 7.  The efficacy and adequacy of continuous ambulatory peritoneal dialysis.

Authors:  G Wu; D Kim; D G Oreopoulos
Journal:  Ulster Med J       Date:  1985-08

8.  Ferrokinetics in patients on CAPD: influence of CAPD on the anemia of uremia.

Authors:  H B Lee; S W Koh; H S Park
Journal:  Korean J Intern Med       Date:  1986-01       Impact factor: 2.884

9.  Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.

Authors:  Myoung Nam Bae; Su Hyun Kim; Young Ok Kim; Dong Chan Jin; Ho Chul Song; Euy Jin Choi; Yong-Lim Kim; Yon-Su Kim; Shin-Wook Kang; Nam-Ho Kim; Chul Woo Yang; Yong Kyun Kim
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.